{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:52:38Z","timestamp":1791474758157,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007065","name":"Universit\u00e0 degli Studi di Salerno","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Although dalbavancin is currently approved for the treatment of ABSSIs, several studies suggest its efficacy and tolerance as long-term therapy for other off-label indications requiring prolonged intravenous antibiotic administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a prospective nationwide study of dalbavancin use in real-life settings for both approved and off-label indications analysing for each case the clinical and microbiological characteristics of infection the efficacy and safety of treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the study period (from December 2018 to July 2021), the ID specialists from 14 different centres enrolled 223 patients treated with dalbavancin [141 males (63%) and 82 females (37%); male\/female ratio 1.72; mean age 59 (SD 17.2) years, (range 15\u201396). Most patients in the study population (136\/223; 61.0%) came from community rather than health care facilities and most of them were visited in Infectious Diseases wards (93\/223; 41.7%) and clinics (55\/223; 24.7%) even though some patients were cured in other settings, such as surgery wards (18\/223; 8.1%), orthopaedic wards (11\/223; 4.9%), Emergency Rooms (7\/223; 3.1%) and non-surgical other than ID wards (6\/223; 2.7%). The most common ID diagnoses were osteomyelitis (44 cases\/223; 19.7%; of which 29 acute and 15 chronic osteomyelitis), cellulitis (28\/223; 12.5%), cutaneous abscess (23\/223; 10.3%), orthopaedic prosthesis-associated infection (22\/223; 9.9%), surgical site infection (20\/223; 9.0%) and septic arthritis (15\/223; 6.7%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, by virtue of its PK\/PD properties, dalbavancin represents a valuable option to daily in-hospital intravenous or outpatient antimicrobial regimens also for off-label indications requiring a long-term treatment of Gram-positive infections.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-024-02176-2","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T06:02:20Z","timestamp":1707285740000},"page":"1297-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry"],"prefix":"10.1007","volume":"52","author":[{"given":"Silvano","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Lichtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Brugnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Santantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Brindicci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Carrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spolti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Luzzati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Schiaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Tacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Quintieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Trecarichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Italian Society of Infectious, Tropical Diseases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2176_CR1","first-page":"313","volume":"23","author":"S Esposito","year":"2015","unstructured":"Esposito S, Noviello S, Leone S. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Infez Med. 2015;23:313\u20137.","journal-title":"Infez Med"},{"key":"2176_CR2","doi-asserted-by":"publisher","unstructured":"Barber\u00e1n J, de la Cuerda A, Barber\u00e1n LC (2021) Dalbavancin. Rev Esp Quimioter 34:26\u201328. https:\/\/doi.org\/10.37201\/req\/s01.07.2021","DOI":"10.37201\/req\/s01.07.2021"},{"key":"2176_CR3","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169\u201379. https:\/\/doi.org\/10.1056\/NEJMoa1310480.","journal-title":"N Engl J Med"},{"key":"2176_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40121-021-00577-6","volume":"11","author":"G B\u00e9raud","year":"2022","unstructured":"B\u00e9raud G, Maupetit JC, Darras A, Vimont A, Blachier M. Dalbavancin in real life: economic impact of prescription timing in french hospitals. Infect Dis Ther. 2022;11:435\u201349. https:\/\/doi.org\/10.1007\/s40121-021-00577-6.","journal-title":"Infect Dis Ther"},{"key":"2176_CR5","first-page":"270","volume":"21","author":"F Palmieri","year":"2013","unstructured":"Palmieri F, Alberici F, Deales A, et al. Early discharge of infectious disease patients: an opportunity or extra cost for the Italian Healthcare System? Infez Med. 2013;21:270\u20138.","journal-title":"Infez Med"},{"key":"2176_CR6","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/antibiotics11101377","volume":"11","author":"M Mazzitelli","year":"2022","unstructured":"Mazzitelli M, Gatti M, Scaglione V, et al. Off-label use of dalbavancin for sequential treatment of spondylodiscitis by methicillin-resistant staphylococcus aureus: a retrospective single-centre experience. Antibiotics (Basel). 2022;11:1377. https:\/\/doi.org\/10.3390\/antibiotics11101377.","journal-title":"Antibiotics (Basel)"},{"key":"2176_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/antibiotics11050563","volume":"11","author":"F Hanses","year":"2022","unstructured":"Hanses F, Dolff S, Trauth J, Seimetz M, Hagel S. A multicentre, prospective, and retrospective registry to characterize the use, effectiveness, and safety of dalbavancin in german clinical practice. Antibiotics (Basel). 2022;11:563. https:\/\/doi.org\/10.3390\/antibiotics11050563.","journal-title":"Antibiotics (Basel)"},{"key":"2176_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/1120009X.2017.1311398","volume":"29","author":"S Esposito","year":"2017","unstructured":"Esposito S, Bassetti M, Concia E, De Simone G, De Rosa FG, Grossi P, et al. Diagnosis and management of skin and soft-tissue infections (SSTI) A literature review and consensus statement: an update. J Chemother. 2017;29:197\u2013214.","journal-title":"J Chemother."},{"key":"2176_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12879-015-1071-0","volume":"15","author":"LG Miller","year":"2015","unstructured":"Miller LG, Eisenberg DF, Liu H, Chang CL, Wang Y, Luthra R, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005\u20132010. BMC Infect Dis. 2015;15:362.","journal-title":"BMC Infect Dis"},{"key":"2176_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/QCO.0000000000000239","volume":"29","author":"S Esposito","year":"2016","unstructured":"Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29:109\u201315.","journal-title":"Curr Opin Infect Dis"},{"key":"2176_CR11","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3201\/eid1509.081228","volume":"15","author":"J Edelsberg","year":"2009","unstructured":"Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerging Infect Dis. 2009;15:1516\u20138.","journal-title":"Emerging Infect Dis"},{"key":"2176_CR12","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1128\/AAC.00649-12","volume":"56","author":"F Marra","year":"2012","unstructured":"Marra F, Patrick DM, Chong M, McKay R, Hoang L, Bowie WR. Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use. Antimicrob Agents Chemother. 2012;56:6243\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"2176_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1086\/605434","volume":"49","author":"DJ Pallin","year":"2009","unstructured":"Pallin DJ, Espinola JA, Leung DY, Hooper DC, Camargo CA Jr. Epidemiology of dermatitis and skin infections in United States physicians\u2019 offices, 1993\u20132005. Clin Infect Dis. 2009;49:901\u20137.","journal-title":"Clin Infect Dis"},{"key":"2176_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/1120009X.2022.2075170","volume":"34","author":"S Esposito","year":"2022","unstructured":"Esposito S, Pagliano P, De Simone G, et al. Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry. J Chemother. 2022;34:524\u201333. https:\/\/doi.org\/10.1080\/1120009X.2022.2075170.","journal-title":"J Chemother"},{"key":"2176_CR15","first-page":"301","volume":"25","author":"S Esposito","year":"2017","unstructured":"Esposito S, De Simone G. Update on the main MDR pathogens: prevalence and treatment options. Infez Med. 2017;25:301\u201310.","journal-title":"Infez Med"},{"key":"2176_CR16","unstructured":"Shahini Shams Abadi M, Nikokar I, Hoseini Alfatemi SM, Malekzadegan Y, Azizi A, Sedigh Ebrahim-Saraie H. Epidemiology of Panton-Valentine Leukocidin harbouring Staphylococcus aureus in cutaneous infections from Iran: a systematic review and meta-analysis. Infez Med. 2017;25:217\u201323."},{"key":"2176_CR17","first-page":"99","volume":"23","author":"S Leone","year":"2015","unstructured":"Leone S, Noviello S, Boccia G, De Caro F, Esposito S. Methicillin-resistant Staphylococcus aureus infections: role of daptomycin\/b-lactams combination. Infez Med. 2015;23:99\u2013104.","journal-title":"Infez Med"},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/107662902760190671","volume":"8","author":"C Cascone","year":"2002","unstructured":"Cascone C, Santagati M, Noviello S, Iannelli F, Esposito S, Pozzi G, et al. S. Macrolide-resistance genes in clinical isolates of Streptococcus pyogenes. Microb Drug Resist. 2002;8:129\u201332.","journal-title":"Microb Drug Resist."},{"key":"2176_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijantimicag.2016.04.011","volume":"48","author":"S Esposito","year":"2016","unstructured":"Esposito S, Bassetti M, Bonnet E, Bouza E, Chan M, De Simone G, et al. Hot topics in the diagnosis and management of skin and soft-tissue infections. Int J Antimicrob Agents. 2016;48:19\u201326.","journal-title":"Int J Antimicrob Agents"},{"key":"2176_CR20","first-page":"3","volume":"26","author":"S Esposito","year":"2018","unstructured":"Esposito S, Noviello S, De Caro F, Boccia G. New insights into classification, epidemiology and microbiology of SSTIs, including diabetic foot infections. Infez Med. 2018;26:3\u201314.","journal-title":"Infez Med"},{"key":"2176_CR21","unstructured":"US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. Silver Spring (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2013. 23"},{"key":"2176_CR22","doi-asserted-by":"crossref","unstructured":"Noviello S, Ianniello F, Esposito S. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci J Antimicrob Chemother. 2001;48:283\u2013286","DOI":"10.1093\/jac\/48.2.283"},{"key":"2176_CR23","doi-asserted-by":"crossref","unstructured":"Gatti M, Andreoni M, Pea F, Viale P. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical need. Drug Design Dev Ther 2021;15:3349\u201378","DOI":"10.2147\/DDDT.S313756"},{"key":"2176_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106069","volume":"56","author":"G Thomas","year":"2020","unstructured":"Thomas G, Henao-Mart\u00ednez AF, Franco-Paredes C, Chastain DB. Treatment of osteoarticular, cardiovascular, intravascular-catheter related and other complicated infections with dalbavancin and oritavancin: a systematic review. Int J Antimicrob Agents. 2020;56: 106069. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106069.","journal-title":"Int J Antimicrob Agents"},{"key":"2176_CR25","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1080\/14787210.2021.1828865","volume":"20","author":"N Monteagudo-Mart\u00ednez","year":"2022","unstructured":"Monteagudo-Mart\u00ednez N, Sol\u00eds-Garc\u00eda Del Pozo J, Nava E, Ikuta I. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022;20:1477\u201389. https:\/\/doi.org\/10.1080\/14787210.2021.1828865.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2176_CR26","doi-asserted-by":"crossref","unstructured":"Bouza E, Valerio M, Soriano A, Morata L, Garc\u00eda Carus E, Rodr\u00edguez-Gonz\u00e1lez C, Hidalgo-Tenorio MC, Plata A, Mu\u00f1oz P, Vena A on behalf of the DALBUSE Study Group. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. International Journal of Antimicrobial Agents 2018;51:571\u201377","DOI":"10.1016\/j.ijantimicag.2017.11.008"},{"key":"2176_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac120","author":"L Morata","year":"2022","unstructured":"Morata L, Aguado JM, Salavert M, Pasquau J, M\u00edguez E, Mu\u00f1oz P, Rossell\u00f3 I, Almirant B. Dalbavancin in clinical practice in Spain: a 2 year retrospective study. JAC Antimicrob Resist. 2022. https:\/\/doi.org\/10.1093\/jacamr\/dlac120.","journal-title":"JAC Antimicrob Resist"},{"key":"2176_CR28","doi-asserted-by":"publisher","unstructured":"Arrieta-Loitegui, Caro-Teller JM, Ortiz-P\u00e9rez S, L\u00f3pez-Medrano F, San Juan-Garrido R, Ferrari-Piquero JM. Effectiveness, safety and cost analysis of dalbavancin in clinical\u00a0practice. Eur J Hosp Pharm 2022;29:55\u201358. https:\/\/doi.org\/10.1136\/ejhpharm-2020-002315","DOI":"10.1136\/ejhpharm-2020-002315"},{"key":"2176_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/idr14020032","volume":"14","author":"K Taylor","year":"2022","unstructured":"Taylor K, Williamson J, Luther V, Stone T, Johnson J, Gruss Z, Russ-Friedman C, Ohl C, Beardsley J. Evaluating the use of dalbavancin for Off-label indications. Infect Dis Rep. 2022;14:266\u201372. https:\/\/doi.org\/10.3390\/idr14020032.","journal-title":"Infect Dis Rep"},{"key":"2176_CR30","unstructured":"Lueking R, Wei W, Mang NS, Ortwine JK, Meisner J. evaluation of dalbavancin use on clinical outcomes, cost-savings, and adherence at a large safety net hospital. Microbiol Spect 1; 1"},{"key":"2176_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","volume":"54","author":"A Dinha","year":"2019","unstructured":"Dinha A, Durana C, Pavese P, Khatchatourianc L, Monnind B, Bleibtreue A, Denis E, Etienne C, Rouanes N, Mahieui R, Bouchandj F, Davidoa B, Lotte R, Cabaretl P, Camou F, Chavanet P, Assi A, Limonta S, Lechiche C, Riour R, Courjons J, Illes G, Lacassin-Beller F, Senneville E, On behalf of the Dalbavancin French Study Group. French national cohort of first use of dalbavancin: A high proportion of off-label use. Int J Antimicrob Agents. 2019;54:668\u201372.","journal-title":"Int J Antimicrob Agents"},{"key":"2176_CR32","doi-asserted-by":"publisher","first-page":"0700","DOI":"10.3390\/antibiotics9100700","volume":"9","author":"L Ajaka","year":"2020","unstructured":"Ajaka L, Heil E, Schmalzle S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics. 2020;9:0700. https:\/\/doi.org\/10.3390\/antibiotics9100700.","journal-title":"Antibiotics"},{"key":"2176_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jgar.2019.03.015","volume":"18","author":"M Bartoletti","year":"2019","unstructured":"Bartoletti M, Mikusb E, Pascale R, Giannella M, Tedeschia S, Calvib S, Tentic E, Fabio Tumietto F, Pierluigi VP. Clinical experience with dalbavancin for the treatment of deep sternal wound infection. J Glob Antimicrob Res. 2019;18:195\u20138.","journal-title":"J Glob Antimicrob Res"},{"issue":"6","key":"2176_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jiph.2023.04.015","volume":"16","author":"CT Baltin","year":"2023","unstructured":"Baltin CT, Wulf C, Rongisch R, et al. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis. J Infect Public Health. 2023;16(6):955\u201363. https:\/\/doi.org\/10.1016\/j.jiph.2023.04.015.","journal-title":"J Infect Public Health."},{"key":"2176_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jgar.2022.07.018","volume":"30","author":"R Pascale","year":"2022","unstructured":"Pascale R, Maccaro A, Mikus E, et al. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study. J Glob Antimicrob Resist. 2022;30:390\u20134. https:\/\/doi.org\/10.1016\/j.jgar.2022.07.018.","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02176-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:46:05Z","timestamp":1722365165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02176-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02176-2","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"11 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}